Lacosamide Stada (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilising the inactive state of these channels, it reduces repetitive neuronal firing and diminishes hyper‑excitability that leads to seizure activity. This mechanism differs from traditional sodium‑channel blockers that target fast inactivation.

The specific dose of Lacosamide Stada is determined by the prescribing clinician based on the patient’s age, weight, renal function, and concomitant therapies. The prescriber will start with a low dose and may titrate upward to achieve optimal seizure control while monitoring tolerability.

The safety of lacosamide during pregnancy and lactation has not been fully established. It is classified as pregnancy category unknown, and the potential benefits must be weighed against possible risks. Women who are pregnant, planning pregnancy, or nursing should discuss treatment options with their healthcare provider.

To request Lacosamide Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑induced arrhythmias. It is often used when patients require additional seizure control or cannot tolerate alternative agents.

Store at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Lacosamide Stada is taken orally, usually as a tablet, with or without food. The medication should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their clinician and not alter the regimen without medical advice.

Serious adverse reactions can include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal thoughts or behavior, and hypersensitivity reactions. Prompt medical attention is required if any of these events occur.

Lacosamide Stada should be avoided in patients with known hypersensitivity to lacosamide or any of its excipients, and in individuals with significant cardiac conduction disorders unless closely monitored. Caution is also advised for patients with severe renal or hepatic impairment, and it should be prescribed only after a thorough clinical assessment.